Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study
- Written by PR Newswire
MELBOURNE, Australia and SAN FRANCISCO, Oct. 27, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the United States.
BioMUSE is a natural history study that aims to track the progression of...
Read more: Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study